|
|
|
 |
| |
| Scientific Program |
 |
|
|
Thursday, September 6, 2012 |
|
|
|
PLENARY SESSION 1: DEBATES IN APL, AML & CLL |
| |
|
15:30-15:40
15:40-16:15
15:40-15:45
15:45-15:55
15:55-16:05
16:05-16:15 |
Chairpersons opening remarks
Is there a possibility to cure APL without chemotherapy in the future?
Moderator: G. Sagilo, Italy
Yes: M. A. Sanz, Spain 
No: F. Lo-Coco, Italy
Discussion
|
|
16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
|
Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?
Moderator: A.K. Burnett, UK
Yes: B. Falini, Italy
No: C. Schiffer, USA
Discussion
|
|
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45 |
Should the new genetic abnormalities and prognostic factors change our management of CLL patients?
Moderator: R. Foà, Italy
Yes: S. Stilgenbauer, Germany
No: G. Gaidano, Italy
Discussion |
|
|
|
|
17:45-18:15 |
Coffee Break |
|
|
|
|
|
EMERGING STRATEGIES FOR RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA: ADDRESSING UNMET NEEDS |
|
Satellite Symposium Sponsored by ARIAD Pharmaceuticals, Inc. |
|
|
|
|
19:30-21:00 |
Welcome Reception |
|
Friday, September 7, 2012 |
|
|
|
|
08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
|
Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy?
Moderator: M.A. Sanz, Spain
Yes: A.K. Burnett, UK
No: P. Fenaux, France
Discussion
|
|
09:15-09:20
09:15-09:20
09:20-09:30
|
Should older patients with AML be considered for lower intensity approaches rather than 3 & 7?
Moderator: J. Esteve, Spain
Yes: J. Sierra, Spain
No: C. Schiffer, USA
Discussion |
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15 |
Should ‘pediatric’-like strategies be extended over the age of 35?
Moderator: D. Hoelzer, Germany
Yes: J.M. Ribera, Spain
No: J.P. Marie, France
Discussion
|
|
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00 |
Can ALL be managed without chemotherapy / transplant?
Moderator: C. Schiffer, USA
Yes: R. Foà, Italy
No: D. Hoelzer, Germany
Discussion
|
|
12:00-13:00 |
Lunch Break |
|
|
|
|
RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) AND ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): REDEFINING THERAPY FOR THESE DIFFICULT DISEASES |
|
A prIME Oncology Symposium supported by Millennium: The Takeda Oncology Company |
|
|
|
|
14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00 |
Is iron chelation of importance in the management of myelodysplasia?
Moderator: G. Saglio, Italy
Yes: E. Rachmilewitz, Israel
No. C. Schiffer, USA
Discussion
|
|
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45 |
After failure of hypomethylating agent-based therapy in myelodysplastic syndromes: which is the best strategy?
Moderator: C. Schiffer, USA
BMT: N. Kröger, Germany
Investigational drugs: V. Santini, Italy
Discussion
|
|
|
|
15:45-16:15 |
Coffee Break |
|
|
|
|
16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00 |
Is the development of JAK 2 inhibitors an important advance in the treatment of MPNs?
Moderator: A. Vannucchi, Italy
Yes: G. Barosi, Italy
No. T. Barbui, Italy
Discussion
|
|
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45 |
Is the recommended hematocrit target in polycythemia vera evidence-based?
Moderator: R. Hehlmann, Germany
Yes: A. Vannucchi, Italy
No: T. Barbui, Italy
Discussion
|
|
|
|
|
08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15 |
Monoclonal B-cell lymphocytosis: Much ado about nothing?
Moderator: R. Foà, Italy
Yes: E. Montserrat, Spain
No: A.C. Rawstron, UK
Discussion
|
|
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00 |
Is the whole better than the sum of its parts? All ‘fit’ older patients should receive FCR.
Moderator: E. Montserrat, Spain
Yes: S. Stilgenbauer, Germany
No: R. Foà, Italy
Discussion
|
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
SESSION 5: INDOLENT NON-HODGKIN LYMPHOMAS |
| |
|
10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15 |
Should all patients with follicular leukemia receive maintenance therapy?
Moderator: A. Hagenbeek, The Netherlands
Yes: U. Vitolo, Italy
No: E. Kimby, Sweden
Discussion
|
|
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00 |
Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?
Moderator: N. Kröger, Germany
Yes: B. Coiffier, France
No: A. Hagenbeek, The Netherlands
Discussion
|
|
|
|
12:00-13:00 |
Lunch Break |
|
|
|
SESSION 7: HODGKIN'S DISEASE |
| |
|
14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00 |
Do we have one or two shots for cure in advanced Hodgkin’s disease? Kairos or Chronos?
Moderator: P.L. Zinzani, Italy
Pro Chronos: late intensification: J. Connors, Canada
Pro Kairos: early intensification: A. Engert, Germany Discussion
|
|
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45 |
Should therapy for HD be modified by the results of the early PET?
Moderator: J. Connors, Canada
Yes: P.L. Zinzani, Italy
No: A. Engert, Germany
Discussion
|
|
|
|
15:45-16:15 |
Coffee Break |
|
16:15-17:45 |
|
SESSION 9: AGGRESSIVE LYMPHOMAS |
| |
16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00 |
Is there a role for RT in localized DLBCLs?
Moderator: C. Haioun, France
Yes: J. Yahalom, USA No: B. Coiffier, France Discussion
|
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45 |
Is there a role for ASCT for the initial management of high risk DLBCLs?
Moderator: B. Coiffier, France
Yes: C. Haioun, France
No: J. Connors, Canada
Discussion
|
|
|
|
|
Saturday, September 8, 2012 |
|
|
|
| 08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15 |
Are TKI sufficient for the treatment of CML, or should TKI be combined with other agents or treatment modalities?
Moderator: G. Saglio, Italy
Yes: R. Hehlmann, Germany
No: M. Baccarani, Italy
Discussion
|
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00 |
Should patients treated with second line TKIs be considered for allo BMT?
Moderator: R. Hehlmann, Germany
Yes: E. Olavarria, Spain
No: J.L. Steegmann, Spain
Discussion
|
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
SESSION 12: HEMOGLOBINOPATHIES |
| |
10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15 |
Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors?
Moderator: E. Rachmilewitz, Israel
Yes: E. Angelucci, Italy
No: G. Rodgers, USA
Discussion
|
|
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00 |
Is there a rationale for treatment of sickle cell anemia except for acute complications?
Moderator: G. Rodgers, USA
Yes: S. Sheth, USA
No: J.L. Vives Corrons, Spain
Discussion
|
|
12:00-13:00 |
Lunch Break |
|
|
|
|
CONTEMPORARY MANAGEMENT OF CHRONIC PHASE CML: BROADENING THE PLAYING FIELD |
|
A prIME Oncology Symposium supported by Teva Oncology |
|
|
|
14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00 |
Are the new molecular and cytogenetic markers useful for the management of MNPs? Moderator: G. Saglio, Italy
Yes: W. Vainchenker, France
No: G. Barosi, Italy
Discussion
|
|
15:00-15:45
15:00-15:05 15:05-15:15
15:15-15:25 15:25-15:45 |
Is serum ferritin a sufficient marker for evaluation and monitoring treatment of iron overload?
Moderator: E. Rachmilewitz, Israel
Yes: A. Piga, Italy
No: Y. Cabantchik, Israel
Discussion
|
|
|
|
15:45-16:15 |
Coffee Break |
|
|
|
PLENARY SESSION 16: DEBATES IN MM & CML |
| |
16:15-16:50
16:15-16:20
16:20-16:30
16:30-16:40
16:40-16:50 |
Preferred 1st line treatment of CML: 2nd generation TKI or optimized Imatinib?
Moderator: J.L. Steegmann, Spain
2nd generation TKI: G. Saglio, Italy
Optimized Imatinib: R. Hehlmann, Germany
Discussion
|
|
16:50-17:25
16:50-16:55
16:55-17:05
17:05-17:15
17:15-17:25 |
MM - Cure versus control: Which is the best strategy?
Moderator: J.F. San-Miguel, Spain
Cure: B. Barlogie, USA
Control: M. Boccadoro, Italy
Discussion
|
|
17:25-17:30 |
Closing Address |
|
|
|
|
|
SESSION 11: MULTIPLE MYELOMA |
| |
08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15 |
Transplant in MM patients: Early versus late
Moderator: J.F. San-Miguel, Spain
Early: A. Nagler, Israel
Late: M. Boccadoro, Italy
Discussion
|
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00 |
Is there a role for maintenance therapy?
Moderator: M. Boccadoro, Italy
Yes: A. Palumbo, Italy
No: J.F. San-Miguel, Spain
Discussion
|
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
|
10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15 |
Should anti-infection prophylaxis be given before / after BMT ?
Moderator: A. Nagler, Israel
Yes: R. Martino, Spain
No: E. Olavarria, Spain
Discussion
|
| 11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00 |
Are all the GFs the same?
Moderator: R. Martino, Spain
Yes: G. Gaidano, Italy
No: M. Shapiro, Israel
Discussion
|
|
|
|
12:00-13:00 |
Lunch Break |
|
|
|
|
|
14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00 |
What should be the next step after failure of steroids in ITP – splenectomy versus Rituximab or TPO mimetics?
Moderator: M.M. Samama, France Splenectomy & Rituximab: R. Stasi, UK TPO mimetics: N. Cooper, UK Discussion
|
|
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45 |
New anticoagulants: Monitoring or not Monitoring?
Mod: N. Cooper, UK
Monitoring: M.M. Samama, France
Not Monitoring: A. Falanga, Italy
Discussion
|
|
|
|
|
|
|
WebStudio.co.il